Dawson James Securities launched coverage of Know Labs (OTCQB:KNWN) with a “buy” rating and price target of $7. The stock closed at $1.59 on Feb. 7.
“Know Labs is driving what could be a significant paradigm shift in how we measure everything from glucose levels to alcohol to oxygen levels in the blood, instantly and with a high degree of accuracy, all via a blue-tooth wearable device like a watch,” writes analyst Jason Kolbert.
“This technology has the potential to change everything,” he added, noting that internal clinical testing is underway, setting the stage for rapid clinical development and potential FDA approval via the de novo pathway.
Mr. Kolbert explained that the technology utilizes electromagnetic energy across a wide range of the spectrum from visible light and infrared to radio and microwave wavelengths to perform analytics (AI processing), which accurately identifies and quantitates its target.
The first selected indication is targeting glucose levels (HbA1c) in Type 2 diabetic patients.
Mr. Kolbert said that over the next two years, the company plans to complete product refinements and finalize the KnowU production units. He said management is preparing to initiate a clinical program based on input from regulators and a pre-submission meeting with the FDA is the next step.
